Franklin Resources Inc Chemo Centryx, Inc. Transaction History

Franklin Resources Inc

$334 Billion
Q3 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $169,733 - $396,580	7,656 New	7,656 $395,000
Q3 2019 Nov 14, 2019	SELL	$6.47 - $8.96 $8.68 Million - $12 Million	-1,341,997 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$8.31 - $14.85 $336,555 - $601,425	-40,500 Reduced 2.93%	1,341,997 $12.5 Million
Q4 2018 Feb 12, 2019	SELL	$9.15 - $12.26 $577,365 - $773,606	-63,100 Reduced 4.36%	1,382,497 $15.1 Million
Q3 2018 Nov 13, 2018	SELL	$10.49 - $13.72 $730,104 - $954,912	-69,600 Reduced 4.59%	1,445,597 $18.3 Million
Q2 2018 Aug 14, 2018	SELL	$10.62 - $13.98 $1.83 Million - $2.41 Million	-172,217 Reduced 10.21%	1,515,197 $20 Million
Q1 2018 May 10, 2018	SELL	$5.9 - $14.99 $1.81 Million - $4.61 Million	-307,383 Reduced 15.41%	1,687,414 $22.9 Million
Q4 2017 Feb 14, 2018	SELL	$5.53 - $8.42 $351,155 - $534,670	-63,500 Reduced 3.09%	1,994,797 $11.9 Million
Q3 2017 Nov 13, 2017	BUY	$6.5 - $10.69 $13.4 Million - $22 Million	2,058,297	2,058,297 $15.3 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.